Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.
Sponsor: Alcyone Therapeutics, Inc
This PHASE1 trial investigates Brainstem Glioma and Neoadjuvant Therapy and is currently completed. Alcyone Therapeutics, Inc leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE1
-
May 2023 — Jun 2023 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Sep 2022 — May 2023 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Completed → Active Not Recruiting
-
May 2020 — Aug 2020 [monthly]
Completed PHASE1
-
Mar 2020 — May 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE1
-
May 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jul 2017 — May 2019 [monthly]
Recruiting PHASE1
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alcyone Therapeutics, Inc
- Clinica Universidad de Navarra, Universidad de Navarra
- DNAtrix, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .